MAKING THE FIRST YEAR MATTER
October 26, 2021 |
*Mind+Matter closes its first year of business celebrating more than £4 million of new business wins in the UK *The global agency launched in Jan 21 has also been awarded a ‘Communique’ award for ‘Excelling in multi-channel campaigns’ for its work with CSL Behring, alongside six further award commendations and wins *The agency offers a ‘health first, sector second’ approach with access to sector experts with unparalleled breadth and depth of capabilities *The growth has led to more than 60 new hires globally, and senior promotions to the UK leadership team alongside the launch of Gravity.ai – a first of its kind global healthcare intelligence data platform
Mind+Matter(an Ashfield Health company, part of UDG Healthcare), a ‘global creative powerhouse in health’ is celebrating its first year of business after securing more than £4 million in new business revenue across key strategic wins that span pharma, medical devices, consumer and animal health clients.
Since the launch of its new proposition in January 2021 following the merger of Pegasus, Ashfield Digital and Creative and Cambridge Biomarketing, the UK Mind+Matter team, led by Corrina Safeio, has gone from strength to strength, drawing on the expertise of its world-class experts based globally.
New senior roles include the promotion of Ian Rayfrom Associate Creative Director to Creative Director, and Kesha Tansey to Client Director. Ian and Kesha join the UK Mind+Matter leadership team and will pay a key role in shaping the future strategy and direction of the agency.
Safeio says it’s already very clear by the raft of new business wins that the health sector needs a deeply interconnected, cross-sector response to both existing clients and new client challenges.
“It’s been a phenomenal first year for Mind+Matter and I’m extremely proud of our talented team and what we have been able to accomplish together. Creating meaningful experiences by bringing data and emotion together to drive behaviour change is at the heart of what we do, day in day out. It’s this proposition alongside our health first, sector second approach that has chimed most with clients –existing and new.”
At the heart of the Mind+Matter offer is CHANGE, a behavioural science-led strategic methodology co-created with the internationally recognised Centre for Behaviour Change at University College London (itself an expert voice in the public health response to Covid-19).
In its first year, Mind+Matter also launched Gravity.ai – a first of its kind global healthcare intelligence data platform. Gravity.ai incorporates artificial intelligence, predictive analytics, data modelling and scientific human consultancy to better understand audiences, behaviour and channel performance, ensuring clients get the best value for their investment.
Safeio adds: “Covid has shown how our individual health is also a truly global issue and personalised communications have never been more important. Matched with our deep earned, owned and paid expertise, Gravity.ai allows us to discover meaningful links between demographics, technologies, and customer behaviours and track the changing dynamics of HCP, patient and consumer communications in a rapidly shifting digital world. This powers our planning model CHANGE, along with proven behavioural science. It’s powerful stuff that delivers impactful, measurable results.”
Ben Beckley leads the new agency from Boston in the US, along with Managing Directors Corrina Safeio and Carina Whitridge, who head up the EMEA and US regions respectively.
This content was provided by Inizio
Company Details
Latest Content from Inizio
What oncologists really want from booth strategy
Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30...
How smart spaces and real-time strategy transformed ASCO® 2025
Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs - it was also a showcase for how technology is redefining congress engagement. Supporting...
The science is shifting in oncology: Are you ready to evolve with it?
Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic...
Reimagine health with Inizio.
At Inizio, we provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access. Our experts guide you through each...
Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development
Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...
Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot
This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...
Navigating the future of AI: Insights from EphMRA’s one day meeting in London
Authored by: Ellie Forde and Mark Braund, Directors
Research conducted for Johnson and Johnson published in scientific journal
Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.
Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance
The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...
Autoimmune conditions: Living With syndicated patient reports
The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...